FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793732307> ?p ?o ?g. }

• W2793732307 abstract "Since cisplatin achieved clinical success, transition metal platinum (Pt) drugs have been effectively used for the treatment of cancer. Iridium (Ir) compounds are considered to be potential alternatives to Pt compounds, as they possess promising anticancer effects with minor side effects. Platelet activation is associated with the metastasis and progression of cancer, and also with arterial thrombosis. Therefore, it is necessary to develop novel, effective antithrombotic agents. An Ir (III)‑derived complex, [Ir (Cp*) 1‑(2‑pyridyl)‑3‑(3‑methoxyphenyl)imidazo[1,5‑a]pyridine Cl]BF4 (Ir‑3), was developed as a novel antiplatelet drug. Ir‑3 exerted more potent inhibitory activity on platelet aggregation stimulated by collagen compared with other agonists, including thrombin. In collagen‑activated platelets, Ir‑3 also inhibited adenosine trisphosphate release, intracellular Ca+2 mobilization and surface P‑selectin expression, as well as the phosphorylation of phospholipase Cγ2 (PLCγ2), protein kinase C (PKC), protein kinase B (Akt) and c‑Jun N‑terminal kinase (JNK) 1, but not p38 mitogen‑activated protein kinase or extracellular signal‑regulated kinases. Ir‑3 did not markedly affect phorbol 12, 13‑dibutyrate‑stimulated platelet aggregation. Neither the adenylate cyclase inhibitor SQ22536 nor the guanylate cyclase inhibitor 1H‑[1, 2, 4] oxadiazolo [4,3‑a]quinoxalin‑1‑one significantly reversed the Ir‑3‑mediated inhibition of platelet aggregation. Furthermore, Ir‑3 had no considerable diminishing effects on OH radical signals in collagen‑stimulated platelets or Fenton reaction solution. In conclusion, Ir‑3 serves a novel function in the inhibition of platelet aggregation through inhibiting the PLCγ2‑PKC cascade, and the subsequent suppression of Akt and JNK1 activation. Therefore, Ir‑3 may be a potential novel therapeutic agent for the treatment of thromboembolic disorders, or the interplay between platelets and tumor cells which contributes to tumor cell proliferation and progression." @default.
• W2793732307 created "2018-03-29" @default.
• W2793732307 creator A5016567936 @default.
• W2793732307 creator A5018862640 @default.
• W2793732307 creator A5020583107 @default.
• W2793732307 creator A5028798231 @default.
• W2793732307 creator A5037029677 @default.
• W2793732307 creator A5048629716 @default.
• W2793732307 creator A5051718665 @default.
• W2793732307 creator A5080501644 @default.
• W2793732307 date "2018-02-07" @default.
• W2793732307 modified "2023-09-27" @default.
• W2793732307 title "Novel iridium (III)‑derived organometallic compound for the inhibition of human platelet activation" @default.
• W2793732307 cites W119510731 @default.
• W2793732307 cites W1968497165 @default.
• W2793732307 cites W1976365078 @default.
• W2793732307 cites W1984241869 @default.
• W2793732307 cites W1985373505 @default.
• W2793732307 cites W1987373035 @default.
• W2793732307 cites W1988212011 @default.
• W2793732307 cites W1996247217 @default.
• W2793732307 cites W1996405087 @default.
• W2793732307 cites W2006917025 @default.
• W2793732307 cites W2028362773 @default.
• W2793732307 cites W2029325522 @default.
• W2793732307 cites W2036145275 @default.
• W2793732307 cites W2053228115 @default.
• W2793732307 cites W2077944086 @default.
• W2793732307 cites W2079323372 @default.
• W2793732307 cites W2081491399 @default.
• W2793732307 cites W2085165002 @default.
• W2793732307 cites W2086080786 @default.
• W2793732307 cites W2086244375 @default.
• W2793732307 cites W2101386911 @default.
• W2793732307 cites W2102924446 @default.
• W2793732307 cites W2103205445 @default.
• W2793732307 cites W2108349218 @default.
• W2793732307 cites W2112919363 @default.
• W2793732307 cites W2144099695 @default.
• W2793732307 cites W2165938620 @default.
• W2793732307 cites W2208023807 @default.
• W2793732307 cites W2236405981 @default.
• W2793732307 cites W2322751526 @default.
• W2793732307 cites W2335031785 @default.
• W2793732307 cites W2484611740 @default.
• W2793732307 cites W4236053983 @default.
• W2793732307 cites W56507834 @default.
• W2793732307 doi "https://doi.org/10.3892/ijmm.2018.3472" @default.
• W2793732307 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5846649" @default.
• W2793732307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29436605" @default.
• W2793732307 hasPublicationYear "2018" @default.
• W2793732307 type Work @default.
• W2793732307 sameAs 2793732307 @default.
• W2793732307 citedByCount "3" @default.
• W2793732307 countsByYear W27937323072018 @default.
• W2793732307 crossrefType "journal-article" @default.
• W2793732307 hasAuthorship W2793732307A5016567936 @default.
• W2793732307 hasAuthorship W2793732307A5018862640 @default.
• W2793732307 hasAuthorship W2793732307A5020583107 @default.
• W2793732307 hasAuthorship W2793732307A5028798231 @default.
• W2793732307 hasAuthorship W2793732307A5037029677 @default.
• W2793732307 hasAuthorship W2793732307A5048629716 @default.
• W2793732307 hasAuthorship W2793732307A5051718665 @default.
• W2793732307 hasAuthorship W2793732307A5080501644 @default.
• W2793732307 hasBestOaLocation W27937323071 @default.
• W2793732307 hasConcept C184235292 @default.
• W2793732307 hasConcept C185592680 @default.
• W2793732307 hasConcept C195794163 @default.
• W2793732307 hasConcept C203014093 @default.
• W2793732307 hasConcept C2778597717 @default.
• W2793732307 hasConcept C3018697912 @default.
• W2793732307 hasConcept C51551487 @default.
• W2793732307 hasConcept C55493867 @default.
• W2793732307 hasConcept C62478195 @default.
• W2793732307 hasConcept C75217442 @default.
• W2793732307 hasConcept C86803240 @default.
• W2793732307 hasConcept C89560881 @default.
• W2793732307 hasConcept C97029542 @default.
• W2793732307 hasConcept C98274493 @default.
• W2793732307 hasConceptScore W2793732307C184235292 @default.
• W2793732307 hasConceptScore W2793732307C185592680 @default.
• W2793732307 hasConceptScore W2793732307C195794163 @default.
• W2793732307 hasConceptScore W2793732307C203014093 @default.
• W2793732307 hasConceptScore W2793732307C2778597717 @default.
• W2793732307 hasConceptScore W2793732307C3018697912 @default.
• W2793732307 hasConceptScore W2793732307C51551487 @default.
• W2793732307 hasConceptScore W2793732307C55493867 @default.
• W2793732307 hasConceptScore W2793732307C62478195 @default.
• W2793732307 hasConceptScore W2793732307C75217442 @default.
• W2793732307 hasConceptScore W2793732307C86803240 @default.
• W2793732307 hasConceptScore W2793732307C89560881 @default.
• W2793732307 hasConceptScore W2793732307C97029542 @default.
• W2793732307 hasConceptScore W2793732307C98274493 @default.
• W2793732307 hasLocation W27937323071 @default.
• W2793732307 hasLocation W27937323072 @default.
• W2793732307 hasLocation W27937323073 @default.
• W2793732307 hasLocation W27937323074 @default.
• W2793732307 hasOpenAccess W2793732307 @default.
• W2793732307 hasPrimaryLocation W27937323071 @default.
• W2793732307 hasRelatedWork W1976734851 @default.

• next